BMS swooped on Karuna towards the end of last year, shortly after AbbVie agreed an $8.7 billion deal to acquire Cerevel Therapeutics, another company developing a schizophrenia drug with a novel ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics in 2023 and the drug's approval last September ended a decades-long drought in new-mechanism therapies for ...

Cobenfy’s launch is tracking against expectations, having surpassed 30,000 total scripts following an FDA approval in late September, according to Lenkowsky. However, a Leerink Partners analysis ...

The United States-based Karuna Foundation has awarded a USD 1 million grant to the Tarayana Foundation to support the construction of disaster-resilient homes for Bhutan’s most vulnerable communities.

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell ...

Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million. The deal ...

Mineralys reports Phase 2 trial success for lorundrostat, showing BP and kidney improvements in CKD patients with favorable safety results.

Company to showcase breakthrough imaging agents advancing precision medicine in neurology and oncologyREDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha ...

The startup and its management come from Scorpion Therapeutics. Lilly’s acquisition of Scorpion closed in March, a deal that committed up to $2.5 billion for that biotech’s most advanced ...

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to ...